A Phase IIb, Randomized, Double-blind Study in Patients with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Patients with an Inadequate Response to Methotrexate
Peterfy C, Buch M, Choy E, Schett G, Parsons-Rich D, Patel A, Zima Y, Le Bolay C, Genovese M (2020)
Publication Type: Conference contribution
Publication year: 2020
Journal
Publisher: WILEY
City/Town: HOBOKEN
Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY
Authors with CRIS profile
Involved external institutions
Spire Sciences LLC
United States (USA) (US)
Cardiff University
United Kingdom (GB)
University of Manchester
United Kingdom (GB)
EMD Serono
United States (USA) (US)
Merck KGaA
Germany (DE)
Stanford University
United States (USA) (US)
United States (USA) (US)
Cardiff University
United Kingdom (GB)
University of Manchester
United Kingdom (GB)
EMD Serono
United States (USA) (US)
Merck KGaA
Germany (DE)
Stanford University
United States (USA) (US)
How to cite
APA:
Peterfy, C., Buch, M., Choy, E., Schett, G., Parsons-Rich, D., Patel, A.,... Genovese, M. (2020). A Phase IIb, Randomized, Double-blind Study in Patients with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Patients with an Inadequate Response to Methotrexate. In ARTHRITIS & RHEUMATOLOGY. HOBOKEN: WILEY.
MLA:
Peterfy, Charles, et al. "A Phase IIb, Randomized, Double-blind Study in Patients with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Patients with an Inadequate Response to Methotrexate." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2020.
BibTeX: Download